Yubo Biotech Narrows Losses Amidst Zero Revenue, Asset Decline

TL;DR

**YBGJ is a speculative bet, as zero revenue and declining assets make its path to profitability highly uncertain despite reduced losses.**

AI Summary

Yubo International Biotech Ltd (YBGJ) reported a net loss of $310,152 for the three months ended September 30, 2025, a significant improvement from the $621,053 net loss in the same period of 2024. For the nine months ended September 30, 2025, the net loss was $902,288, compared to $1,628,906 in 2024. Revenue from sales of products and services remained at $0 for both the three and nine months ended September 30, 2025, a decrease from $3,488 in revenue for the nine months ended September 30, 2024. Total operating expenses decreased to $310,134 for the three months ended September 30, 2025, from $532,764 in 2024, primarily due to reduced occupancy costs, which fell from $175,646 to $46,920. The company's total assets declined from $1,534,832 as of December 31, 2024, to $953,211 as of September 30, 2025, while total liabilities also decreased substantially from $4,832,522 to $2,555,316 over the same period. Cash on hand increased slightly to $10,926 from $7,015 at the beginning of the period. The company issued 50,600,343 ordinary shares, raising $2,530,000 in additional paid-in capital during the nine months ended September 30, 2025.

Why It Matters

Yubo International Biotech's continued lack of revenue generation, despite a reduction in net loss, signals a critical challenge for investors. The significant decline in total assets by 37.9% and total liabilities by 47.1% suggests a substantial restructuring or scaling back of operations, which could impact future growth prospects and competitive positioning in the biotech sector. For employees, this could indicate job insecurity or a shift in operational focus. Customers, if any, might face uncertainty regarding product availability or support. The broader market will watch if YBGJ can monetize its biotech research, particularly in stem cell technologies, to justify its valuation and compete with more established players.

Risk Assessment

Risk Level: high — The company reported $0 in revenue for the three and nine months ended September 30, 2025, indicating a complete lack of sales, which is a critical risk for any operating business. Furthermore, total assets decreased by 37.9% from $1,534,832 at December 31, 2024, to $953,211 at September 30, 2025, while cash on hand remains extremely low at $10,926, highlighting severe liquidity concerns and dependence on external financing.

Analyst Insight

Investors should exercise extreme caution and consider YBGJ a high-risk, speculative investment given the zero revenue and minimal cash. Await clear evidence of revenue generation and a sustainable business model before considering any investment.

Financial Highlights

debt To Equity

N/A

revenue

$0

operating Margin

N/A

total Assets

$953,211

total Debt

$0

net Income

-$310,152

eps

N/A

gross Margin

N/A

cash Position

$10,926

revenue Growth

-100.0%

Revenue Breakdown

Key Numbers

• $0 — Revenue (For the three and nine months ended September 30, 2025, indicating no sales.)
• $310,152 — Net loss (3 months) (For the three months ended September 30, 2025, a 50% reduction from $621,053 in 2024.)
• $902,288 — Net loss (9 months) (For the nine months ended September 30, 2025, a 44.6% reduction from $1,628,906 in 2024.)
• $953,211 — Total Assets (As of September 30, 2025, a 37.9% decrease from $1,534,832 at December 31, 2024.)
• $2,555,316 — Total Liabilities (As of September 30, 2025, a 47.1% decrease from $4,832,522 at December 31, 2024.)
• $10,926 — Cash (As of September 30, 2025, a slight increase from $7,015 at December 31, 2024.)
• 50,600,343 — Ordinary shares issued (During the nine months ended September 30, 2025, increasing total shares outstanding.)
• $2,530,000 — Additional Paid in Capital (Raised from the issuance of ordinary shares during the nine months ended September 30, 2025.)
• $46,920 — Occupancy expenses (3 months) (For the three months ended September 30, 2025, a significant reduction from $175,646 in 2024.)

Key Players & Entities

• Yubo International Biotech Limited (company) — Registrant and U.S. holding company
• Platinum International Biotech Co., Ltd. (company) — Wholly-owned subsidiary of Yubo International Biotech Limited
• Yubo International Biotech (Beijing) Limited (company) — Variable Interest Entity (VIE) operating in China
• Bloomberg (company) — Financial news organization
• SEC (regulator) — U.S. Securities and Exchange Commission
• New York (location) — State of incorporation for Yubo International Biotech Limited
• Cayman Islands (location) — Jurisdiction of incorporation for Platinum International Biotech Co., Ltd.
• People's Republic of China (location) — Primary operating region for Yubo Beijing

FAQ

Risk Factors

• Zero Revenue Generation [high — financial]: The company has reported $0 in revenue from sales of products and services for both the three and nine months ended September 30, 2025. This indicates a complete lack of commercialization or sales activity, posing a significant risk to the company's ability to generate income and sustain operations.
• Significant Asset and Liability Reduction [medium — financial]: Total assets decreased by 37.9% from $1,534,832 to $953,211, and total liabilities decreased by 47.1% from $4,832,522 to $2,555,316 between December 31, 2024, and September 30, 2025. While a reduction in liabilities can be positive, the substantial decrease in assets alongside zero revenue suggests potential asset liquidation or a scaling down of operations.
• High Accumulated Deficit [high — financial]: The company has an accumulated deficit of $7,478,641 as of September 30, 2025. This substantial deficit, coupled with zero revenue, highlights the company's long-standing unprofitability and reliance on external funding.
• Dependence on Shareholder Funding [medium — operational]: The company raised $2,530,000 through the issuance of 50,600,343 ordinary shares during the nine months ended September 30, 2025. This reliance on equity financing for operations, especially with no revenue, indicates a high dependence on capital markets and investor sentiment.
• Reduced Operating Expenses [low — operational]: Total operating expenses decreased to $310,134 from $532,764 year-over-year, primarily due to a significant drop in occupancy costs from $175,646 to $46,920. While cost reduction is generally positive, this could also signal a contraction in business activities or facilities.
• VIE Structure Complexity [medium — regulatory]: The company utilizes a Variable Interest Entity (VIE) structure with Yubo Beijing. Such structures can introduce complex regulatory and legal risks, particularly concerning enforceability and compliance with Chinese regulations, which could impact the company's consolidated financial reporting and operations.

Industry Context

Yubo International Biotech operates in the biotechnology sector, which is characterized by high research and development costs, long product development cycles, and significant regulatory hurdles. The industry is highly competitive, with companies often relying on substantial funding rounds to advance their pipelines. The current trend involves a focus on specialized therapies and precision medicine, demanding significant investment in innovation and clinical trials.

Regulatory Implications

The company's use of a Variable Interest Entity (VIE) structure in China presents potential regulatory risks. Changes in Chinese foreign investment or VIE regulations could impact the company's ability to consolidate its VIE's financial results or control its operations. Furthermore, as a biotech company, Yubo is subject to stringent regulations from bodies like the FDA for product development and approval.

What Investors Should Do

1. Monitor revenue generation closely.
2. Scrutinize future funding rounds and use of proceeds.
3. Assess the strategy behind asset and liability reductions.
4. Evaluate the long-term strategy for overcoming the accumulated deficit.

Key Dates

• 2025-09-30: End of Q3 2025 — Reported $0 revenue and a net loss of $310,152 for the quarter, with total assets at $953,211 and liabilities at $2,555,316.
• 2025-01-01: Start of 2025 Fiscal Year — Beginning of the period where the company raised $2,530,000 through share issuance and saw a reduction in operating expenses.
• 2024-12-31: End of Fiscal Year 2024 — Company had total assets of $1,534,832 and total liabilities of $4,832,522.
• 2021-01-14: Reverse Merger with Platinum International Biotech Co. Ltd. — This transaction established the current corporate structure and business focus of Yubo International Biotech Limited.

Glossary

Variable Interest Entity (VIE)

A structure used by companies to bypass foreign ownership restrictions in certain industries, where a domestic entity holds the licenses and permits, and a foreign-invested enterprise controls the domestic entity through contractual agreements. (Yubo International Biotech Limited uses a VIE structure with Yubo Beijing, which can introduce regulatory and legal complexities.)

Additional Paid in Capital

The amount of money a company receives from selling stock above its par value. (The company raised $2,530,000 in Additional Paid in Capital from share issuances, indicating funding from investors.)

Accumulated Deficit

The total net losses of a company that have not been offset by net income since its inception. (Yubo International Biotech has a significant accumulated deficit of $7,478,641, highlighting its history of unprofitability.)

Operating lease right of use asset

An asset recognized under accounting standards for the right to use an asset for the lease term, typically for property or equipment. (This asset decreased significantly from $478,765 to $138,604, reflecting reduced occupancy costs.)

Reverse Merger

A transaction where a private company acquires a public shell company, thereby becoming a publicly traded company without a traditional IPO. (Yubo International Biotech was formed through a reverse merger, which is a common method for biotech companies to access public markets.)

Year-Over-Year Comparison

Compared to the prior year's comparable period, Yubo International Biotech has significantly reduced its net loss, with the three-month loss down 50% to $310,152 and the nine-month loss down 44.6% to $902,288. This improvement is largely driven by a substantial decrease in operating expenses, particularly occupancy costs, which fell from $175,646 to $46,920 for the quarter. However, revenue remains at $0, a stark contrast to the $3,488 reported in the prior year's nine-month period. Total assets and liabilities have also decreased substantially, indicating a potential restructuring or scaling back of operations, while cash has seen a slight increase due to significant equity financing.

Key Financial Figures

• $0.001 — vember 13, 2025. Class A Common Stock, $0.001 par value 170,416,343 Class B Common

Filing Documents

• yubo_10q.htm (10-Q) — 1067KB
• yubo_ex311.htm (EX-31.1) — 13KB
• yubo_ex312.htm (EX-31.2) — 13KB
• yubo_ex321.htm (EX-32.1) — 5KB
• yubo_ex322.htm (EX-32.2) — 5KB
• yubo_10qimg2.jpg (GRAPHIC) — 31KB
• yubo_10qimg1.jpg (GRAPHIC) — 55KB
• 0001640334-25-002083.txt ( ) — 5782KB
• yubo-20250930.xsd (EX-101.SCH) — 62KB
• yubo-20250930_lab.xml (EX-101.LAB) — 290KB
• yubo-20250930_cal.xml (EX-101.CAL) — 52KB
• yubo-20250930_pre.xml (EX-101.PRE) — 267KB
• yubo-20250930_def.xml (EX-101.DEF) — 171KB
• yubo_10q_htm.xml (XML) — 973KB

Notes to Consolidated Financial Statements

Notes to Consolidated Financial Statements F-5 Item 2. – Management's Discussion and Analysis of Financial Condition and Results of Operations 6 Item 3. – Quantitative and Qualitative Disclosures about Market Risk 17 Item 4. – Controls and Procedures 17

- OTHER INFORMATION

PART II - OTHER INFORMATION Item 1. – Legal Proceedings 19 Item 1A. – Risk Factors 19 Item 2 – Unregistered Sales of Equity Securities and Use of Proceeds 19 Item 3. – Defaults Upon Senior Securities 19 Item 4. – Mine Safety Disclosures 19 Item 5. – Other Information 19 Item 6. – Exhibits 19

SIGNATURES

SIGNATURES 20 2 Table of Contents ABOUT THIS QUARTERLY REPORT In this Quarterly Report on Form 10-Q (this "Quarterly Report"), unless otherwise specified, the terms "we," "our," "us," our "Company," the "Company," or the "Registrant" refer to Yubo International Biotech Limited, a U.S. holding company and a New York corporation and its wholly owned subsidiaries, including Platinum International Biotech Co., Ltd., a company organized under the laws of the Cayman Islands ("Platinum"), Platinum International Biotech (Hong Kong) Limited, a company organized under the laws of Hong Kong and a wholly owned subsidiary of Platinum ("Platinum HK"), Yubo International Biotech (Chengdu) Limited, a company organized under the laws of the People's Republic of China and a wholly owned subsidiary of Platinum HK ("Yubo Chengdu" or "Yubo WFOE" or "WFOE"), and Yubo Global Biotechnology (Chengdu) Co., Ltd., a company organized under the laws of the People's Republic of China and a wholly owned subsidiary of Platinum HK ("Yubo Global"). We are a U.S. holding company primarily operating through our wholly owned subsidiary, Platinum. Platinum is not a Chinese operating company but a Cayman Islands holding company, which in turn operates in China through its subsidiaries and contractual arrangements with a variable interest entity ("VIE"), Yubo International Biotech (Beijing) Limited, a company organized under the laws of the People's Republic of China and, through contractual arrangements with us, the Chinese operating company. None of our Company, Platinum, or Platinum HK, each as a holding company, conducts any day-to-day business operations in China. The term "Yubo Beijing" refers to Yubo International Biotech (Beijing) Limited, a VIE organized under the laws of the People's Republic of China, including its wholly-owned subsidiary, Phoenix Club Bio-Medical Technology (Chengdu) Co., Ltd, a company organized under the laws of the People's Republic of China ("Yubo Phoenix"), and

: FINANCIAL INFORMATION

PART I: FINANCIAL INFORMATION

Financial Statements

Item 1. Financial Statements YUBO INTERNATIONAL BIOTECH LIMITED INDEX TO UNAUDITED CONSOLIDATED FINANCIAL STATEMENTS For the three and nine months ended September 30 , 2025 and 2024 Table of Contents Consolidated Balance Sheets (Unaudited) F-1 Consolidated Statements of Operations and Comprehensive Loss (Unaudited) F-2 Consolidated Statements of Changes in Shareholders' Equity (Unaudited) F-3 Consolidated Statements of Cash Flows (Unaudited) F-4

Notes to Consolidated Financial Statements (Unaudited)

Notes to Consolidated Financial Statements (Unaudited) F-5 5 Table of Contents YUBO INTERNATIONAL BIOTECH LIMITED CONSOLIDATED BALANCE SHEETS (Expressed in US Dollars) September 30, December 31, 2025 2024 (Unaudited) Current assets Cash $ 10,926 $ 7,015 Receivables 114,287 164,984 Prepaid expenses 202,054 196,417 Inventory 37,889 36,953 Due from related parties 284,407 277,382 Total Current Assets 649,563 682,751 Property and equipment, net 84,645 205,913 Intangible assets, net 43,241 50,523 Operating lease right of use asset 138,604 478,765 Lease security deposit 37,158 116,880 Total Assets $ 953,211 $ 1,534,832 LIABILITIES AND SHAREHOLDERS' EQUITY Current liabilities Accounts payable and accrued expenses (including accounts payable and accrued expenses of VIE without recourse to the Company of $ 891,838 and $ 880,787 as of September 30, 2025 and December 31, 2024, respectively) $ 957,197 $ 1,037,836 Advances from prospective customers/distributors (including advances from prospective customers/distributors of VIE without recourse to the Company of $ 434,765 and $ 424,026 as of September 30, 2025 and December 31, 2024, respectively) 434,765 424,026 Due to related parties (including due to related parties without recourse to the Company of $ 874,683 and $ 2,741,830 as of September 30, 2025 and December 31, 2024, respectively) 1,024,750 2,891,895 Operating lease liabilities – current (including operating lease liabilities - current of VIE without recourse to the Company of $ 138,604 and $ 367,992 as of September 30, 2025 and December 31, 2024, respectively) 138,604 367,992 Total Current Liabilities 2,555,316 4,721,749 Non-current liabilities Operating lease liabilities - non-current (including operating lease liability – non- current of VIE without recourse to the Company of $ 7,812 and $ 110,773 as of September 30, 2025 and December 31, 2024, respectivel

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS For the three and nine months ended September 30, 2025 and 2024 (Unaudited) NOTE 1 – ORGANIZATION Yubo International Biotech Limited (formerly Magna-Lab Inc.) (the "Company"), a New York corporation, acquired Platinum International Biotech Co. Ltd. ("Platinum") in a "reverse merger" transaction on January 14, 2021. On January 14, 2021 (the "Closing Date"), the Company closed a voluntary share exchange transaction with Platinum International Biotech Co., Ltd., a company organized under the laws of the Cayman Islands ("Platinum"), pursuant to that certain Agreement and Plan of Share Exchange, dated January 14, 2021 (the "Exchange Agreement"), by and among the Company, Platinum, Yubo International Biotech (Beijing) Limited, a company organized under the laws of the People's Republic of China ("PRC") ("Yubo Beijing"), and certain selling stockholders named therein. In accordance with the terms of the Exchange Agreement, on the Closing Date, the Company issued a total of 117,000,000 shares of its Class A common stock to the Selling Stockholders, who were then stockholders of Platinum (the "Selling Stockholders"), in exchange for 100% of the issued and outstanding capital stock of Platinum (the "Exchange Transaction"). As a result of the Exchange Transaction, the Selling Stockholders acquired more than 99 % of the Company's issued and outstanding capital stock, Platinum became the Company's wholly-owned subsidiary, and the Company acquired the business and operations of Platinum and Yubo Beijing. Immediately prior to the Exchange Transaction, the Company had 117,875,323 shares of Class A common stock and 4,447 shares of Class B common stock issued and outstanding. Immediately after the Exchange Transaction and the surrender and cancellation of 116,697,438 shares held by Lina Liu, the controlling shareholder, Chief Financial Officer, Treasurer and Secretary of the Company, the Company had 118,177,885 shares of Class A co

View Full Filing

View this 10-Q filing on SEC EDGAR